Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.
about
Group B Streptococcus vaccine: state of the artIdentification of major outer surface proteins of Streptococcus agalactiaeSurface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiaeImmunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.Identification of a universal Group B streptococcus vaccine by multiple genome screen.Implication of TLR- but not of NOD2-signaling pathways in dendritic cell activation by group B Streptococcus serotypes III and V.Interaction of neonatal phagocytes with group B streptococcus: recognition and response.Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model.Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period.L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci.Transmission probabilities and durations of immunity for three pathogenic group B Streptococcus serotypesRole of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cellsGroup B Streptococcus: global incidence and vaccine development.Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinToll-like receptor 2 deficiency is associated with enhanced severity of group B streptococcal disease.Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase.The CovS/CovR acid response regulator is required for intracellular survival of group B Streptococcus in macrophages.The group B streptococcal C5a peptidase is both a specific protease and an invasin.Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999.Streptococcus agalactiae Non-Pilus, Cell Wall-Anchored Proteins: Involvement in Colonization and Pathogenesis and Potential as Vaccine Candidates.Group B Streptococcal Colonization, Molecular Characteristics, and Epidemiology.
P2860
Q26796438-BE5005AC-D36E-4463-8BB1-FF2680116F9FQ31039249-F008F619-4E50-49E3-845B-3D38AB141B1FQ33719415-400E7106-C7DB-4B18-83BB-0815EA75BEAEQ34008692-CE4BD8FD-A040-4F15-8B87-71B3F6A96C39Q34184513-F4F14595-7FDC-4DF8-9ED0-ECD91C3E9C60Q34194488-B9A33690-4706-4BFD-99DE-13546A588904Q34313096-C5B5F05E-A2AF-43F4-90E5-E38EBF8345B4Q34600971-5C6FAD6B-C617-4BDC-92C9-E8AE0F3EE721Q34681095-5A98D88B-0556-47FA-A03F-DB42586881E6Q35541855-B99F3D7B-C787-4B49-B27D-C3AC0C467E65Q35913598-BCDE169A-3C7E-44A6-AF6D-099E55CD2413Q35917434-8F486407-A780-4E3D-B6D1-2AC791B40AE4Q36018153-A4BD1BC9-4C86-4463-BC0A-62A09089BEF7Q36082709-60BD874E-FD88-4976-807D-2336C49A6D0DQ36596215-96FD0055-DB86-4036-B854-9A2572A686FEQ36646803-17FD9373-4E2C-4351-B8F6-EA86A27028E0Q36746962-B61C4CB7-9F6F-47E7-88B2-9BA4012B65ECQ37144975-2EB39A76-27BD-40E0-9C01-E1ED7A661AA7Q37258108-EA777A3C-E3BE-45F0-A888-0A235BD5A8B7Q38625811-762F81C7-47D9-4473-BA86-81B1C9D35C82Q39397002-B9A802A2-AF27-4C71-90B7-AFD1DF1386B2Q39654984-632F26C9-02F8-4F2D-92DC-6CF45A3E1C49Q51710821-C636D064-D3D3-4F0E-BBE3-2DEB94C06A24Q52568338-CD7A841B-F983-4852-B5AC-92F69ADFD75BQ52624533-05CCE59F-DDA5-464B-82FD-171BD928B66B
P2860
Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antibody against surface-bound ...... lling of group B streptococci.
@ast
Antibody against surface-bound ...... lling of group B streptococci.
@en
Antibody against surface-bound ...... lling of group B streptococci.
@nl
type
label
Antibody against surface-bound ...... lling of group B streptococci.
@ast
Antibody against surface-bound ...... lling of group B streptococci.
@en
Antibody against surface-bound ...... lling of group B streptococci.
@nl
prefLabel
Antibody against surface-bound ...... lling of group B streptococci.
@ast
Antibody against surface-bound ...... lling of group B streptococci.
@en
Antibody against surface-bound ...... lling of group B streptococci.
@nl
P2093
P2860
P1476
Antibody against surface-bound ...... lling of group B streptococci.
@en
P2093
S B Olmsted
P2860
P304
P356
10.1128/IAI.69.4.2302-2308.2001
P407
P577
2001-04-01T00:00:00Z